To determine how broadly AZD5991 (Mcl-1 inhibition) combines with AZD8186 or capivasertib and to identify determinants of combination sensitivity, both combinations were assessed in a panel of 44 breast cancer cell lines (Fig. 7) [39]. This evidence concerns the gene MCL1 and breast carcinoma.